EX-99.2 3 d596161dex992.htm EX-99.2 EX-99.2

Slide 1

Webcast - 29th / 30th May 2018 (ASX: IMM, NASDAQ: IMMP) New Data from Ongoing Melanoma Study and Clinical Development Strategy Update Exhibit 99.2


Slide 2

The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Immutep and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company’s filings to the ASX and SEC for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.  No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Immutep’s control.  Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.  Because actual results could differ materially to assumptions made and Immutep’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.  Additionally, the INSIGHT investigator sponsored clinical trial described in this presentation is controlled by the lead investigator and therefore Immutep has no control over this clinical trial. This presentation should not be relied on as a recommendation or forecast by Immutep. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. Notice: Forward Looking Statements


Slide 3

LAG-3 Overview


Slide 4

Evolution of Checkpoint Therapies LAG-3 has the potential to be the next meaningful checkpoint target… Evolution of Immuno-Oncology Therapies Keytruda Keytruda/ chemo combination Opdivo/ anti-LAG-3 Combination(1) 2011 `12 `13 `14 `15 `16 `17 `18 `19 2020* Opdivo/ Yervoy combination Yervoy Timeline of Immune Checkpoint Discovery Existing immuno-oncology therapies are CTLA-4, PD-1 and PD-L1 antagonists and are approved for many disease indications However, only 15 - 40% of solid tumors in patients respond to monotherapy Immuno-oncology market will be worth approximately US$14 billion in 2019, rising to US$34 billion by 2024, with checkpoint therapies accounting for most of the market(2) Notes: (1) Expected timing, actual results may differ (BMS ASCO 2017 Investor Presentation) (2) Global Data, Immuno-Oncology Strategic Insight: Multi-Indication and Market Size Analysis (May 2016)


Slide 5

LAG-3 Therapeutic Landscape Overview Immutep is the leader in developing LAG-3 modulating therapeutics Sources: GlobalData, company websites, clinical trials.gov, and sec.gov Information as of April 23, 2018, includes also trials which are only listed as planned, includes also trials where the company may not be the sponsor Indicates one product; size indicates stage of development, green = product either developed by Immutep or under license from Immutep Indicates No. of patients on trials


Slide 6

eftilagimod alpha (efti, IMP321)


Slide 7

Eftilagimod alpha (IMP321) Dimeric, very stable, high affinity for DC Antigen presenting cell (APC) activator Unique mechanism of action and potentially first-in-class Efti is a soluble recombinant fusion protein consisting of the Fc portion of a human antibody and the four extracellular domains of LAG-3 CH3 CH2 Hinge CH1 VH VL CL Human IgG1 Soluble LAG-3 CH3 CH2 Hinge IMP321 “LAG-3Ig” D4 D3 D2 D1 D1 D2 D3 D4 MHC II binding site


Slide 8

The only APC targeting LAG-3 product currently in clinical development A unique approach (“turning cold tumors into hot tumors” with LAG-3) Synergistic with other IO agents Efti - Innovative LAG-3 IO Product Candidate Efti, an MHC II agonist (eftilagimod alpha, IMP321) : APC activator Boost and sustain the CD8+ T cell responses Activate multiple immune cell subsets “PUSHING THE ACCELERATOR ON IMMUNE RESPONSES” “RELEASING THE BRAKE ON THE T CELL” LAG-3 antagonist antibodies: immune checkpoint inhibitor increase cytotoxicity of the pre-existing CD8 T cell response


Slide 9

Notes Expected timing of data readouts and actual results and timing may differ In combination with KEYTRUDA® (pembrolizumab); clinical trial is currently planned and not yet active INSIGHT Investigator Initiated Trial (IST) is controlled by lead investigator; Immutep is not the sponsor, but supplies IMP321 Efti - Clinical Development / Description


Slide 10

Efti (IMP321) TACTI-mel Results (as of 9th May 2018 )


Slide 11

Problem: Low monocyte numbers at baseline leads to poor efficacy of anti-PD-1 therapy Solution: efti (IMP321) increases monocyte numbers in cancer patients New Rationale for Combining efti (IMP321) with PD-1 Antagonists (pembrolizumab) 1.00 0.75 0.50 0.25 0.00 Time (months) Overall Survival Classical monocytes > 19 % Classical monocytes < 19 % Source: Krieg et al., Nat. Med. 24, 2018. N=51 Monocytes are important for response and survival to pembrolizumab à efti (IMP321) increases monocytes sustainably above threshold of 19 % à response to pembrolizumab more likely N=15 Source: AIPAC stage 1 Classical Monocytes %


Slide 12

Part A: efti (IMP321) at 1, 6 and 30 mg s.c. every 2 weeks starting with cycle 5 of pembrolizumab à Status: recruitment completed; interim results on next slides Part B: efti (IMP321) at 30 mg s.c. every 2 weeks starting with cycle 1 of pembrolizumab à Status: 3 pts enrolled w/o DLTs Pembrolizumab (Keytrudaâ) 2 mg/kg every 3 weeks i.v. part A and B Phase I, multicenter, open label, dose escalation 24 patients, 4 cohorts of 6 patients Efti (IMP321) + anti-PD-1 (Keytrudaâ) Recommended Phase II dose, safety and tolerability Primary Objective Recommended dose for Phase II with efti (IMP321) + pembrolizumab Safety + tolerability Other Objectives PK and PD of IMP321, response rate, time to next treatment, PFS Efti (IMP321) in Melanoma TACTI-mel (IO combination) – Trial Design 7 sites in Australia TACTI-mel = Two ACTive Immunotherapeutics in melanoma preliminary data, status 9th May 2018


Slide 13

preliminary data, status 9th May 2018 Study Scheme Part A: irRC…Immune-Related Response Criteria, PFS- progression free survival, FU – follow-up Efti (IMP321) in Melanoma TACTI-mel (IO combination) – Details Part A Patient population Part A: Patients with unresectable or metastatic melanoma with asymptomatic progression or suboptimal response after 3 cycles of pembrolizumab


Slide 14

Best Overall Response acc. to irRC N = 18 (%) irCR 1 (6 %) irPR# 5 (28 %)# irSD 6 (33 %) irPD 6 (33 %) Best overall response rate (ORR) 6 (33 %) Patients with tumor shrinkage 9 (50 %) Disease control rate 12 (66 %) Baseline Characteristics N = 18 (%) Elevated LDH 7 (39%) Metastasis stage M1c 15 (83 %) Pre-treated with BRAF/MEK/ipilimumab 4 (22 %) irPD/irSD to pembro after 3 cycles 12 (67 %) # - incl. 1 pt with complete disappearance of all target lesions; CR acc. to RECIST 1.1 Waterfall Plot* (starting after 4 cycles of pembrolizumab) Patients very late stage of disease (M1c, elevated LDH) Majority not responding to pembrolizumab à Tumor shrinkage in 50 % of these patients incl. 2 pts with complete disappearance of all target lesions Efti (IMP321) in Melanoma TACTI-mel (IO combination) – Results after Start of Combo (1) preliminary data, status 9th May 2018 * - acc to irRC


Slide 15

durable responses Spiderplot* Cohort 1-3 – May 2018 preliminary data, status 9th May 2018 Efti (IMP321) in Melanoma TACTI-mel (IO combination) – Results after Start of Combo (2) Complete responses of target lesions occurred after 11 and 18 months --> combination takes time to act 3 (out of 12 = 25 %) durable responses in first 2 dose levels à treatment and FU ongoing Treatment and follow-up of 3 patients in 3rd cohort (30 mg) ongoing Conclusion * - acc to irRC


Slide 16

Efficacy: Metastatic Melanoma All lesions disappeared à CR (confirmed) patient without treatment and disease free Tumor progression preliminary data, status 9th May 2018 Efti (IMP321) in Melanoma TACTI-mel (IO combination) – Single Case at 1 mg efti


Slide 17

Pre pembro 9 months after start of combo Target lesion: chest wall; Non-target lesion: Left common iliac LN preliminary data, status 9th May 2018 Σ TL (irRC) 100 mm² 25 mm² 25 mm² 25 mm² 0 mm² In % 0 % -75 % -75 % -75 % -100 % Response NA irPR irPR irPR irPR Sum of target lesions (TL) acc to irRC Complete disappearance of target lesions à CR acc. to RECIST 1.1 Patient still on pembrolizumab Efti (IMP321) in Melanoma TACTI-mel (IO combination) – Single Case at 6 mg efti


Slide 18

Best Overall Response acc. to irRC (C1/D1 analysis)(1) N = 18 (%) irCR 1 (6%)(1) irPR# 10 (56%)(1),(2) irSD 5 (28%)(1) irPD 2 (11%)(1) Best overall response rate (ORR) 11 (61%)(1) Progression free at 6 months 12 (66%)(1) preliminary data, status 9th May 2018 Overall response rate is 61% and 66% of patients are progression free 6 months after start of pembrolizumab (1) 7/12 (58 %) patients with progression (irPD) or stable disease (irSD) have a benefit by adding IMP321(1) Trial Design TACTI-mel: Combination treatment of efti and pembrolizumab starts at cycle 5 in patients not responding well or progressing on pembrolizumab à difficult to compare to any historical control How does the efficacy looks from the start of pembrolizumab? à Performed analysis of read-outs starting from cycle 1 day 1 of pembrolizumab, including the 4 cycles pembrolizumab monotherapy (“C1/D1 Analysis”) Efti (IMP321) in Melanoma Response Analysis Starting Cycle 1 Day 1 Pembrolizumab Notes Response rates determined by C1/D1 Analysis Includes 1 patient with complete disappearance of all target lesions, CR acc to RECIST1.1


Slide 19

Efti (IMP321) in Melanoma Comparison to historical controls preliminary data, status 9th May 2018 TACTI-Mel enrolled ipilimumab (ipi) naive and ipi pre-treated patients à Keynote-002 (pre-treated) and Keynote-006 (naive) used for comparison Baseline Characteristics Tacti-Mel (C1/D1 response analysis) Pembro 2 mg/kg N=18 in % KN-006 (ipi naive) Pembro 10 mg/kg n=277 In % KN-002 (ipi pre-treated) Pembro 2 mg/kg n=180 In % Metastasis stage M1c 83% 68% 82% ECOG 1 / 0 22% / 78% 32% / 68% 45% / 55% irCR 6%(1) 6%(2) 2%(2) ORR 61%(1) 33%(2) 21%(2) Progression free at 6 months 66%(1) 46%(2) 34%(2) 61 % response rate(1, 2) and 66 % progression free at 6 months (1, 2) with the PD-1 antagonist pembrolizumab and APC activator eftilagimod alpha in very late stage melanoma How does the data fit in the treatment landscape and in comparison to pembro monotherapy? Notes Response rates determined by C1/D1 Analysis TACTImel used irRC and KN-002 and KN-006 RECIStT1.1


Slide 20

Notes None of them related to combination of IMP321 + pembrolizumab, all in trials in combination with paclitaxel Ongoing trials like randomized part of AIPAC (226 patients), IITs (n=38) or new trials (N=120) not included here Exposure(2) in cancer patients 87 cancer patients in different indications and combinations (see table) Subcutaneous injection every two weeks 52 (~60%) received 6-30 mg efti (IMP321) Efti (IMP321) – Clinical Overview Exposure and Safety Efti (IMP321) has very favorable safety profile up to 30 mg given s.c. every 2 weeks Combination with chemotherapy or PD-1 antagonists is feasible without reaching MTD Combination partner / indication Cancer patients N = 87(2) Efti (IMP321) alone / renal cell cancer 21 with paclitaxel / met. Breast cancer 48 with pembrolizumab / met. melanoma 18 preliminary data, status 9th May 2018 Safety profile in cancer patients No efti (IMP321) related deaths In total 24 SAEs (29%) thereof 4 (5%) (possibly) related to efti(1) No MTD in any combination Most common adverse events: local erythema and any type of injection site reaction up to NCI-CTC grade 2


Slide 21

Efti (IMP321) TACTI-002 - Design


Slide 22

In March 2018 Immutep entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) to evaluate the combination of efti (IMP321) with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a new Phase II clinical trial Efti (IMP321) – Clinical Development Collaboration and Supply Agreement


Slide 23

TACTI-002; a basket trial: Two ACTive Immunotherapeutics in different indications Phase II, multi-national (EU + US + AUS), open label Simons 2 stage; 3 indications; up to 120 pts Response rate; PFS, OS, PK, Biomarker; Safety and tolerability Primary Objective Response rate (iRECIST) Other Objectives Safety, PFS+OS, PK, exploratory biomarker analysis Patient Population Part A: 1st line NSCLC PD-X naive Part B: 2nd line NSCLC, PD-X refractory Part C: 2nd line HNSCC, PD-X naive Treatment 30 mg Efti (IMP321) s.c. 200 mg Pembrolizumab i.v. Efti (IMP321) + Pembrolizumab (Keytrudaâ) for 12 months + max. of 12 months pembrolizumab monotherapy 12-15 sites in Europe / US / Australia Protocol Development + IND preparation ongoing Study start expected Q.4 ‘18 First DMC meeting planned mid ’19 First data expected mid ‘19 Status Report Efti (IMP321) – Clinical Development TACTI-002 Trial Design Notes NSCLC – non-small-cell lung cancer, HNSCC – head and neck squamous cell cancer, DMC – data monitoring comittee, PFS – progression free survival, OS – overall survival, PK – pharmacokinetics, PD-X – any PD-1 or PDL-1 treatment


Slide 24

Efti (IMP321) Summary preliminary data, status 9th May 2018 Very favorable safety profile à no DLT/MTD reached with pembrolizumab à combination feasible and safe Able to induce a IFN-γ type response in patients Response rate of 61 % and progressions free survival rate at 6 months of 66 % in late stage mostly visceral (M1C) melanoma if combined with pembrolizumab(1) Will be investigated in combination with pembrolizumab in 3 new indications starting 2018 Notes Response rates determined by C1/D1 Analysis


Slide 25

Thank you!